AT403917B - Indolderivate - Google Patents

Indolderivate Download PDF

Info

Publication number
AT403917B
AT403917B AT0075293A AT75293A AT403917B AT 403917 B AT403917 B AT 403917B AT 0075293 A AT0075293 A AT 0075293A AT 75293 A AT75293 A AT 75293A AT 403917 B AT403917 B AT 403917B
Authority
AT
Austria
Prior art keywords
compound
formula
metabolically labile
oxy
physiologically acceptable
Prior art date
Application number
AT0075293A
Other languages
German (de)
English (en)
Other versions
ATA75293A (de
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of ATA75293A publication Critical patent/ATA75293A/de
Application granted granted Critical
Publication of AT403917B publication Critical patent/AT403917B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT0075293A 1992-04-16 1993-04-15 Indolderivate AT403917B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
ATA75293A ATA75293A (de) 1997-11-15
AT403917B true AT403917B (de) 1998-06-25

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0075293A AT403917B (de) 1992-04-16 1993-04-15 Indolderivate

Country Status (41)

Country Link
US (4) US5374649A (en, 2012)
EP (1) EP0568136A1 (en, 2012)
JP (2) JPH0649027A (en, 2012)
KR (1) KR100264114B1 (en, 2012)
CN (1) CN1042331C (en, 2012)
AP (1) AP480A (en, 2012)
AT (1) AT403917B (en, 2012)
AU (1) AU666927B2 (en, 2012)
BE (1) BE1006343A5 (en, 2012)
BG (1) BG62136B1 (en, 2012)
BR (1) BR1100323A (en, 2012)
CA (3) CA2094073A1 (en, 2012)
CH (1) CH685630A5 (en, 2012)
CY (1) CY2038B1 (en, 2012)
CZ (1) CZ285799B6 (en, 2012)
DK (1) DK169890B1 (en, 2012)
ES (1) ES2105924B1 (en, 2012)
FI (1) FI106198B (en, 2012)
FR (1) FR2690919B1 (en, 2012)
GB (2) GB9208492D0 (en, 2012)
GE (1) GEP19991704B (en, 2012)
GR (1) GR1001619B (en, 2012)
HK (1) HK95797A (en, 2012)
HU (2) HU217964B (en, 2012)
IL (1) IL105412A (en, 2012)
IS (1) IS3994A (en, 2012)
IT (1) IT1265325B1 (en, 2012)
LU (1) LU88248A1 (en, 2012)
MX (1) MX9302195A (en, 2012)
MY (1) MY112232A (en, 2012)
NO (1) NO301879B1 (en, 2012)
NZ (1) NZ247413A (en, 2012)
OA (1) OA10103A (en, 2012)
PL (1) PL176451B1 (en, 2012)
RO (1) RO113242B1 (en, 2012)
RU (1) RU2129544C1 (en, 2012)
SE (1) SE504336C2 (en, 2012)
SK (1) SK281941B6 (en, 2012)
TW (1) TW224457B (en, 2012)
WO (1) WO1993021153A1 (en, 2012)
ZA (1) ZA932642B (en, 2012)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
KR100314482B1 (ko) * 1993-05-27 2002-02-28 메렐 파마슈티칼스 인크. 3-(인돌-3-일)프로페노산유도체
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (en, 2012) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
WO1998011892A1 (en) * 1996-09-17 1998-03-26 The Regents Of The University Of California Positive ampa receptor modulation to enhance brain neurotrophic factor expression
WO1998014427A1 (en) * 1996-09-30 1998-04-09 Hoechst Marion Roussel, Inc. Nmda (n-methyl-d-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
US6440458B1 (en) * 1998-03-26 2002-08-27 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparations
NZ523812A (en) * 2000-07-31 2004-07-30 Dainippon Pharmaceutical Co Medicaments containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient for treating dementia, dsmnesia, learning deficit and higher brain dysfunction
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
US7582657B2 (en) * 2001-12-10 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
EP1636240A1 (en) * 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
ES2347152T3 (es) * 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
RU2281755C2 (ru) * 2004-04-19 2006-08-20 Пятигорская государственная фармацевтическая академия Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
AU2006264317B2 (en) 2005-07-06 2012-02-23 Sunovion Pharmaceuticals Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
AU2006335174B2 (en) 2006-01-06 2012-09-06 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
KR101294014B1 (ko) * 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
DK2013835T3 (en) 2006-03-31 2015-12-14 Sunovion Pharmaceuticals Inc Preparation of chiral amides and AMINES
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2676432A1 (en) * 2007-01-18 2008-07-24 Sepracor, Inc. Inhibitors of d-amino acid oxidase
EP2154962A4 (en) 2007-05-31 2012-08-15 Sepracor Inc PHENYL-SUBSTITUTED CYCLOALKYLAMINE AS A MONOAMINE RECOVERY INHIBITOR
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010104093A1 (ja) 2009-03-10 2010-09-16 参天製薬株式会社 ４，６－ジクロロ－１ｈ－インドール－２－カルボン酸誘導体又はその塩を有効成分として含有する視神経障害の予防又は治療剤
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
IL248567B (en) 2014-04-30 2022-08-01 Univ Nat Taiwan Use of known compounds as d-amino acid oxidase inhibitors
JP7029129B2 (ja) 2016-09-14 2022-03-03 ユーフェン ジェーン ツェン Ｄ－アミノ酸オキシダーゼ（ｄａａｏ）阻害剤としての新規な置換ベンゾイミダゾール誘導体
CA3067162A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
EP0396124A2 (en) * 1989-05-05 1990-11-07 G.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
WO1992001670A1 (en) * 1990-07-16 1992-02-06 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
WO1992016205A2 (en) * 1991-03-18 1992-10-01 Warner-Lambert Company Novel derivatives of 2-carboxyndoles having pharmaceutical activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
EP0396124A2 (en) * 1989-05-05 1990-11-07 G.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
WO1992001670A1 (en) * 1990-07-16 1992-02-06 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
WO1992016205A2 (en) * 1991-03-18 1992-10-01 Warner-Lambert Company Novel derivatives of 2-carboxyndoles having pharmaceutical activity

Also Published As

Publication number Publication date
HU211826A9 (en) 1995-12-28
DK169890B1 (da) 1995-03-27
HUT70526A (en) 1995-10-30
NO943913L (no) 1994-12-14
DK43193A (da) 1993-10-17
SK124194A3 (en) 1995-05-10
SK281941B6 (sk) 2001-09-11
TW224457B (en, 2012) 1994-06-01
US5374649A (en) 1994-12-20
CA2094076A1 (en) 1993-10-17
IS3994A (is) 1993-10-17
FI106198B (fi) 2000-12-15
GB2266091A (en) 1993-10-20
SE9301241L (sv) 1993-10-17
GR1001619B (el) 1994-07-29
PL176451B1 (pl) 1999-05-31
GEP19991704B (en) 1999-08-05
CN1085212A (zh) 1994-04-13
MX9302195A (es) 1994-03-31
BG62136B1 (bg) 1999-03-31
BG99111A (bg) 1995-05-31
IL105412A (en) 1998-02-22
ITRM930236A0 (it) 1993-04-15
GB9307808D0 (en) 1993-06-02
KR100264114B1 (ko) 2000-11-01
HK95797A (en) 1997-08-08
NO943913D0 (no) 1994-10-14
US5374648A (en) 1994-12-20
CH685630A5 (fr) 1995-08-31
ZA932642B (en) 1994-01-10
FR2690919B1 (fr) 1995-05-05
HU9402975D0 (en) 1995-02-28
GB9208492D0 (en) 1992-06-03
DK43193D0 (da) 1993-04-15
ES2105924A1 (es) 1997-10-16
SE9301241D0 (sv) 1993-04-15
AP480A (en) 1996-03-22
ITRM930236A1 (it) 1994-10-15
CY2038B1 (en) 1998-04-30
EP0568136A1 (en) 1993-11-03
FI944800L (fi) 1994-10-12
AU3692393A (en) 1993-10-21
CZ285799B6 (cs) 1999-11-17
OA10103A (en) 1996-12-18
RU2129544C1 (ru) 1999-04-27
NO301879B1 (no) 1997-12-22
RU94045915A (ru) 1996-09-10
SE504336C2 (sv) 1997-01-13
CA2094073A1 (en) 1993-10-17
JPH0649027A (ja) 1994-02-22
US5510367A (en) 1996-04-23
FI944800A0 (fi) 1994-10-12
AP9300524A0 (en) 1993-04-30
AU666927B2 (en) 1996-02-29
JPH07505407A (ja) 1995-06-15
WO1993021153A1 (en) 1993-10-28
FR2690919A1 (fr) 1993-11-12
IL105412A0 (en) 1993-08-18
IT1265325B1 (it) 1996-10-31
NZ247413A (en) 1995-12-21
US5373018A (en) 1994-12-13
CN1042331C (zh) 1999-03-03
GB2266091B (en) 1995-08-09
CA2094075A1 (en) 1993-10-17
CZ254394A3 (en) 1995-07-12
LU88248A1 (fr) 1994-03-01
RO113242B1 (ro) 1998-05-29
BE1006343A5 (fr) 1994-07-26
BR1100323A (pt) 2000-06-27
ES2105924B1 (es) 1998-07-01
ATA75293A (de) 1997-11-15
HU217964B (hu) 2000-05-28
MY112232A (en) 2001-05-31

Similar Documents

Publication Publication Date Title
AT403917B (de) Indolderivate
DE69032020T2 (de) N-Substituierte 4-Pyrimidinamine und -Pyrimidindiamine, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE69014351T2 (de) Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE68908040T2 (de) 3-(4-Piperidin)-5-(2-sulphonylaminoethyl)-indol-Derivate.
DE69927803T2 (de) Imidazo-pyridin verbindungen, die die sekretion von magensäure hemmen.
DE69325199T2 (de) Triazolopyridazine als Antiasthmatika
DE69015842T2 (de) Nicotinsäurederivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE69304883T2 (de) Xanthin Derivate
DE69716062T2 (de) Benzofuran-derivate und deren verwendung
DE69110254T2 (de) Hydroxychinolonderivate.
WO2001005762A2 (de) Biphenylderivate, ihre herstellung und ihre verwendung als mtp-inhibitor
DE69714265T2 (de) Tetrahydrochinolinderivate als eaa antagonisten
EP0546388A1 (de) Azaheterocyclylmethyl-chromane als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
DE3880396T2 (de) Zur Behandlung von neurodegenerativen Erkrankungen verwendbare Kynurensäurederivate.
DE69622731T2 (de) Tetrahydrochinoline als nmda antagonisten
EP0031080A1 (de) 2-Acylaminomethyl-1,4-benzodiazepine und deren Salze sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69417235T2 (de) IMIDAZO[1,2-a]PYRAZIN-4-ON-DERIVATE ANTAGONISTEN DER AMPA UND NMDA REZEPTOREN
DE69118539T2 (de) Exzitatorische Aminosäureantagonisten
DE69508421T2 (de) SPIRO[HETEROZYCLISCHE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN]-4'-ONE, IHRE HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL
JPH0372467A (ja) ピペラジン誘導体
WO1992014465A1 (de) Verwendung von anellierten tetrahydropyridinessigsäurederivaten für die behandlung neurologischer erkrankungen
DE69926632T2 (de) Tetrahydrochinolinderivate als glycinantagonisten
DE69300373T2 (de) (1H-Indol-1-yl)-2-(Amino)Acetamide und verwandte (1H-Indol-1-yl)-(Aminoalkyl)Amide, Zwischenprodukte, Verfahren zur Herstellung davon und ihre Verwendung als Arzneimittel.
DE60026883T2 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
US4933354A (en) 2-pyrrolidone-5-carboxylic acid compounds useful for the treatment of mental disorders

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee